Anti-TNFα therapy of rheumatoid arthritis: What can we learn about chronic disease?

Novartis Foundation Symposium

Volumn 256, Issue , 2004, Pages 53-69

  Feldmann, Marc ^a   Brennan, Fionula M ^a   Paleolog, Ewa ^a   Cope, Andrew ^a   Taylor, Peter ^a   Williams, Richard ^a   Woody, Jim ^b   Maini, Ravinder N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; BIOSYNTHESIS; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2142756589     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (52)

1. Albani S, Keystone EC, Nelson JL et al 1995 Positive selection in autoimmunity: abnormal immune responses to a bacterial DNAJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med 1:448-152
2. Badger AM, Griswold DE, Kapadia R et al 2000 Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 43:175-183
3. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M 1989a Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 2:S177-S186
4. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M 1989b Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247
5. Brennan FM, Maini RN, Feldmann M 1992 TNFα - a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293-298
6. Brennan FM, Hayes AL, Ciesielski CJ, Green P, Foxwell BMJ, Feldmann M 2002 Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 46:31-41
7. Butler DM, Maini RN, Feldmann M, Brennan FM 1995 Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti-TNFalpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Network 6:225-230
8. Charles P, Elliott MJ, DavisDet al 1999 Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521-1528
9. Cope AP, Aderka D, Doherty M et al 1992 Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 35:1160-1169
10. Cope AP, Londei M, Chu NR et al 1994 Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749-760
11. Di Giovine FS, Meager A, Leung H, Duff GW 1988 Immunoreactive tumour necrosis factor alpha and biological inhibitor(s) in synovial fluids from rheumatic patients. Int J Immunopathol Pharmacol 1:17-26
12. Elliott MJ, Maini RN, Feldmann M et al 1993 Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690
13. Elliott MJ, Maini RN, Feldmann M et al 1994 Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110
14. Feldmann M, Maini RN 2001 Anti-TNFα therapy or rheumatoid arthritis: What have we learned? Annu Rev Immunol 19:163-196
15. Feldmann M, Brennan FM, Chantry D et al 1990 Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49:480-486
16. Feldmann M, Brennan FM, Maini RN 1996a Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
17. Feldmann M, Brennan FM, Maini RN 1996b Rheumatoid arthritis. Cell 85:307-310
18. Fong Y, Tracey KJ, Moldawer LL et al 1989 Antibodies to cachectin/tumor necrosis factor reduce interleukin 1beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 170:1627-1633
19. Gregersen PK, Silver J, Winchester RJ 1987 The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205-1213
20. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M 1991 Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 21:2575-2579
21. Holoshitz J, Klajman A, Drucker I et al 1986 T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage. Lancet 2:305-309
22. Keane J, Gershon S, Wise RP et al 2001 Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1104
23. Kingsley G 1997 Microbial DNA in the synovium - a role in aetiology or a mere bystander? Lancet 349:1038-1039
24. Knight DM, Trinh H, Le J et al 1993 Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453
25. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL 2000 Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47:185-201
26. Li ZW, Chu W, Hu Y et al 1999 The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189:1839-1845
27. Lipsky PE, van der Heijde DMFM, St Clair EW et al 2000a Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New Engl J Med 343:1594-1602
28. Lipsky PE, van der Heijde DMFM, St Clair EW et al 2000b 102 week clinical and radiological results from the ATTRACT trial: A2 year, randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active rheumatoid arthritis despite methotrexate. Arthritis Rheum 47:S242
29. Maini RN, Taylor PC 2000 Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51:207-229
30. Maini RN, Breedveld FC, Kalden JR et al 1998 Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
31. Maini R, St Clair EW, Breedveld F et al 1999 Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
32. Moreland LW, Baumgartner SW, Schiff MH et al 1997 Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147
33. Moreland LW, Schiff MH, Baumgartner SW et al 1999 Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 130:478-486
34. NHS National Institute for Clinical Excellence 2002 Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technical Appraisal Guidance No.36
35. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN 1996 Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 39:1082-1091
36. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, MainiRN1998 Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41:1258-1265
37. Panayi GS, Corrigall VM, Pitzalis C 2001 Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 27:317-334
38. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W 1992 Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-514
39. Rau R 2002 Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61:II70-II73
40. Saklatvala J, Sarsfield SJ, Townsend Y 1985 Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J Exp Med 162:1208-1222
41. Silman AJ, MacGregor AJ, Thomson W et al 1993 Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 32:903-907
42. Silman AJ, Newman J, MacGregor AJ 1996 Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 39:732-735
43. Tak PP, Taylor PC, Breedveld FC et al 1996 Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077-1081
44. Takahashi Y, Murai C, Shibata S et al 1998 Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95:8227-8232
45. Taylor PC, Peters AM, Paleolog E et al 2000 Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38-47
46. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA 1992 Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375-7379
47. Ueno Y, Umadome H, Shimodera M, Kishimoto I, Ikegaya K, Yamauchi T 1993 Human parvovirus B19 and arthritis. Lancet 341:1280
48. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC 2000 Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43:2391-2396
49. Williams RO, Feldmann M, Maini RN 1992 Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784-9788
50. Williams RO, Mason LJ, Feldmann M, Maini RN 1994 Synergy between anti-CD4 and antitumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91:2762-2766
51. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV 1997 IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 278:866-869
52. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ 1989 Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83:876-882